Otros idiomas Modalis Therapeutics Corporation

Acciones

4883

JP3922600006

Diferido Japan Exchange Otros sitios de cotización 08:00:00 16/05/2024			Varia. Cinco días.	Varia. 1 de enero.
66 ^JPY	-5,71 %		-9,33 %	-45,16 %

07/05	Modalis Therapeutics informa de datos que respaldan el desarrollo de una terapia transformadora de edición del epigenoma, MDL-101	CI
30/04	Modalis Therapeutics Corporation presentará datos que respaldan el desarrollo de medicamentos transformadores de edición del epigenoma para el tratamiento de la distrofia muscular en la Cumbre Mundial de Terapia Celular y Génica	CI

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

Modalis Therapeutics Reports Data Supporting Development of a Transformative Epigenome Editing Therapeutic, MDL-101: a First-in-Class Epigenome Editing approach for the Treatment of LAMA2-deficient congenital muscular dystrophy (LAMA2-CMD)	07/05
Modalis Therapeutics Reports Data Supporting Development of a Transformative Epigenome Editing Therapeutic, MDL-101	07/05
Modalis Therapeutics Corporation to Present Data Supporting Development of Transformative Epigenome Editing Medicines for the Treatment of Muscular Dystrophy at the Global Cell & Gene Therapy Summit	30/04
Modalis Announces updated strategic plan and business consolidation of US operation	15/04
Modalis Announces Partnership with Ginkgo Bioworks	15/04
Modalis Therapeutics to See Reduced Expenses of 250 to 350 Million After Cutting Jobs	15/04
Modalis Announces Partnership with Ginkgo Bioworks	12/04
Modalis Therapeutics to Reduce Stated Capital and Capital Reserves	23/02
Japanese Shares Continue to Track Wall Street Higher as Investor Caution Ahead of US Rate Decision Caps Gains	13/12
Modalis Therapeutics, JCR Pharmaceuticals Form Drug Delivery Research Partnership	13/12
Modalis Therapeutics Corporation and JCR Pharmaceuticals Enter into Joint Research Agreement	13/12
Modalis and JCR Pharmaceuticals enter into joint research agreement	13/12
Modalis Therapeutics Corporation announced that it has received ¥505.320864 million in funding from Evolution Capital Management LLC	30/11
Modalis Therapeutics Corporation announced that it expects to receive ¥505.320864 million in funding from Evolution Capital Management LLC	07/11
Modalis Therapeutics Corporation cancelled the transaction announced on September 11, 2023	28/09/23
Modalis Therapeutics Corporation announced that it expects to receive ¥18.77952 million in funding from China Silver Asset Management Hong Kong Limited	11/09/23
Modalis Therapeutics Corporation to Regain Full Rights to MDL-201 and MDL-202 from Astellas Pharma Inc	07/08/23
Modalis Therapeutics Corporation Receives Positive FDA Response for Pre-IND Review for MDL-101 Clinical Development	26/06/23
Modalis Therapeutics to Grant Stock Options	16/06/23
Modalis Therapeutics Corporation Reports Earnings Results for the First Quarter Ended March 31, 2023	12/05/23

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Modalis Therapeutics Corporation

Acciones

4883

JP3922600006

Otros idiomas

Filtros